Status:
COMPLETED
Safety and Effectiveness Assessment of PeGagen® (Pegfilgrastim) in the Prevention of Chemotherapy-induced FN
Lead Sponsor:
Cinnagen
Conditions:
Chemotherapy-induced Neutropenia
Eligibility:
All Genders
18+ years
Brief Summary
The present study was an observational, multicenter, non-interventional, single arm, open label, PMS study conducted in Iran. The primary objective of this study was safety assessment, including the ...
Detailed Description
The present study was an observational, multicenter, non-interventional, single arm, open label, PMS study conducted in Iran. Data was gathered in two booklets, each containing information on four cy...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients aged ≥18 years,
- with the diagnosis of various types of cancers (such as lymphoma, breast, lung, testicular, prostate, ovary and gastrointestinal cancers), receiving first-line chemotherapy regimens with a high FN risk, which PegaGen® is injected due to physician decision.
Exclusion
Key Trial Info
Start Date :
March 29 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 7 2019
Estimated Enrollment :
654 Patients enrolled
Trial Details
Trial ID
NCT04460079
Start Date
March 29 2016
End Date
September 7 2019
Last Update
July 7 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.